DIAH

DIAH 2026

19 – 21 May 2026 | Bruges, Belgium

Project cooperationUpdated on 22 April 2026

MMCR formulation platform - co-development, licensing & investment.

Borg Hemelaer

Business Development Officer at BePharbel Manufacturing

Courcelles, Belgium

About

MMCR™ is a proprietary formulation technology designed to enable gastro‑resistant protection and prolonged‑release behavior in liquid oral formulations. While such performance characteristics are well established for solid dosage forms, they remain a major unmet need in liquid medicines.

Following our ongoing development of a liquid gastro‑resistant esomeprazole formulation for human use, we are expanding the MMCR™ platform into veterinary applications, with an initial focus on companion animals and horses. The objective is to apply the technology to new indications and active pharmaceutical ingredients (APIs), either through co‑development partnerships, licensing of the MMCR™ platform or investment.

Development Status

  • Human program:

Liquid gastro‑resistant esomeprazole formulation under development. With first PoC in a human clinical study.

  • Veterinary program:

Early stage, Evaluation of target APIs and animal‑specific use cases. Partner engagement for co‑development and licensing discussions

Stage

  • TRL 5: Technology validation in relevant environment

Topic

  • Animal Health

Type

  • Research Collaboration
  • Licensing Partner
  • Commercialisation Partner
  • Distribution Partner
  • Investment Partner

Organisation

BePharbel Manufacturing

Courcelles, Belgium

Similar opportunities